This post was originally published on this site
The drug price negotiation program is part of President Joe Biden’s signature Inflation Reduction Act (IRA). The program faces several other court challenges, including from leading industry groups and other drug companies.
‍AstraZeneca said it was filing a legal challenge in a bid to “protect timely access to medicines for orphan indications” in the United States.
